Results 61 to 70 of about 49,826 (161)

Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. [PDF]

Front Endocrinol (Lausanne), 2023
Li CX, Liu LY, Zhang CX, Geng XH, Gu SM, Wang YQ, Liu H, Xie Q, Liang S.   +8 more
europepmc   +1 more source

Impact of Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Exercise‐Induced Pulmonary Hypertension

Pulmonary Circulation
Patients with borderline pulmonary hypertension (PH) often experience shortness of breath or exacerbation of PH during exercise, known as exercise‐induced PH.
Taijyu Satoh, Nobuhiro Yaoita, Satoshi Higuchi, Kotaro Nochioka, Saori Yamamoto, Haruka Sato, Shunsuke Tatebe, Kaito Yamada, Yusuke Yamada, Kohei Komaru, Naoki Chiba, Yuki Sarashina, Ryuichi Mori, Mitsuru Nakada, Hideka Hayashi, Hideaki Suzuki, Hiroyuki Takahama, Hideki Ota, Satoshi Yasuda   +18 more
doaj   +1 more source

Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus. [PDF]

Eur J Nucl Med Mol Imaging, 2023
Geist BK, Brath H, Zisser L, Yu J, Fueger B, Nics L, Patronas EM, Kautzky-Willer A, Hacker M, Rasul S.   +9 more
europepmc   +1 more source

Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we “gliflozin” patients with kidney stone disease?

Brazilian Journal of Nephrology
The prevalence of nephrolithiasis is increasing worldwide. Despite advances in understanding the pathogenesis of lithiasis, few studies have demonstrated that specific clinical interventions reduce the recurrence of nephrolithiasis.
Mauricio de Carvalho, Ita Pfeferman Heilberg   +1 more
doaj   +2 more sources

Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis. [PDF]

Cureus, 2022
Bhalla S, AlQabandi Y, Nandula SA, Boddepalli CS, Gutlapalli SD, Lavu VK, Abdelwahab Mohamed Abdelwahab R, Huang R, Potla S, Hamid P.   +9 more
europepmc   +1 more source

Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. [PDF]

Cardiovasc Diabetol, 2021
Giugliano D, Longo M, Scappaticcio L, Caruso P, Esposito K.   +4 more
europepmc   +1 more source

Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials. [PDF]

Front Endocrinol (Lausanne), 2021
Li D, Liu Y, Hidru TH, Yang X, Wang Y, Chen C, Li KHC, Tang Y, Wei Y, Tse G, Xia Y.   +10 more
europepmc   +1 more source

Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up. [PDF]

Front Pharmacol, 2021
Sardu C, Massetti M, Testa N, Martino LD, Castellano G, Turriziani F, Sasso FC, Torella M, De Feo M, Santulli G, Paolisso G, Marfella R.   +11 more
europepmc   +1 more source

REPURPOSING SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS FOR GEROTHERAPY

Innovation in Aging
Abstract Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are drugs used to treat T2DM, offering benefits such as reduced HbA1c, weight loss, and improved insulin sensitivity/β-cell function. Additionally, they provide significant cardio-renal benefits, although the exact mechanisms are not fully understood.
Solis-Herrera, Carolina, Venna, Venugopal, Lee, Juneyoung   +2 more
openaire   +1 more source

Medication counselling with sodium glucose transporter 2 inhibitor therapy

Indian Journal of Endocrinology and Metabolism, 2014
Sanjay Kalra, Manash P Baruah, Rakesh Sahay   +2 more
openaire   +3 more sources